Log in

Mirati Therapeutics News Headlines (NASDAQ:MRTX)

$97.05
-0.38 (-0.39 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$94.35
Now: $97.05
$99.49
50-Day Range
$96.71
MA: $110.86
$128.97
52-Week Range
$55.11
Now: $97.05
$132.59
Volume459,287 shs
Average Volume773,275 shs
Market Capitalization$3.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.17

Headlines

Mirati Therapeutics (NASDAQ MRTX) News Headlines

Source:
DateHeadline
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional SharesMirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - January 14 at 5:24 PM
Mirati Therapeutics Inc (NASDAQ:MRTX) Major Shareholder Boxer Capital, Llc Acquires 50,000 SharesMirati Therapeutics Inc (NASDAQ:MRTX) Major Shareholder Boxer Capital, Llc Acquires 50,000 Shares
www.americanbankingnews.com - January 14 at 5:16 PM
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters Option To Purchase Additional SharesMirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
www.prnewswire.com - January 14 at 4:15 PM
Mirati Therapeutics prices stock offering at $97.50; shares down 2% premarketMirati Therapeutics prices stock offering at $97.50; shares down 2% premarket
seekingalpha.com - January 10 at 5:19 PM
Mirati Therapeutics Announces Pricing Of Public Offering Of Common StockMirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
finance.yahoo.com - January 9 at 10:16 PM
Mirati Therapeutics Announces Proposed Public Offering of Common StockMirati Therapeutics Announces Proposed Public Offering of Common Stock
www.prnewswire.com - January 8 at 4:11 PM
Mirati Therapeutics (NASDAQ:MRTX) Earns "Buy" Rating from CowenMirati Therapeutics (NASDAQ:MRTX) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - January 7 at 7:56 AM
Mirati Therapeutics Announces Executive Management ChangesMirati Therapeutics Announces Executive Management Changes
finance.yahoo.com - January 6 at 5:25 PM
Heres Why Mirati Therapeutics Jumped 28% in DecemberHere's Why Mirati Therapeutics Jumped 28% in December
www.fool.com - January 4 at 8:35 PM
Here's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO PayHere's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay
finance.yahoo.com - January 3 at 1:55 PM
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare ConferenceMirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - January 2 at 4:52 PM
Commit To Purchase Mirati Therapeutics At $90, Earn 14.6% Using OptionsCommit To Purchase Mirati Therapeutics At $90, Earn 14.6% Using Options
www.nasdaq.com - December 30 at 4:07 PM
Mirati Therapeutics Inc (NASDAQ:MRTX) Short Interest UpdateMirati Therapeutics Inc (NASDAQ:MRTX) Short Interest Update
www.americanbankingnews.com - December 28 at 2:24 PM
Mirati Therapeutics Inc (NASDAQ:MRTX) Receives Consensus Rating of "Buy" from AnalystsMirati Therapeutics Inc (NASDAQ:MRTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 27 at 6:14 AM
FY2022 Earnings Forecast for Mirati Therapeutics Inc (NASDAQ:MRTX) Issued By OppenheimerFY2022 Earnings Forecast for Mirati Therapeutics Inc (NASDAQ:MRTX) Issued By Oppenheimer
www.americanbankingnews.com - December 25 at 8:00 AM
Mirati Therapeutics Reaches Analyst Target PriceMirati Therapeutics Reaches Analyst Target Price
www.nasdaq.com - December 18 at 1:36 PM
Options Traders Expect Huge Moves in Mirati (MRTX) StockOptions Traders Expect Huge Moves in Mirati (MRTX) Stock
finance.yahoo.com - December 18 at 1:36 PM
Mirati Therapeutics: A Classic Philip Fisher Growth StockMirati Therapeutics: A Classic Philip Fisher Growth Stock
seekingalpha.com - December 10 at 2:32 PM
Mirati (MRTX) Reports Q3 Loss, Tops Revenue EstimatesMirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 4 at 9:56 PM
Mirati Therapeutics Reports Third Quarter 2019 Financial ResultsMirati Therapeutics Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 4 at 4:55 PM
The Mirati Therapeutics (NASDAQ:MRTX) Share Price Gained 1921% And Shareholders Are JubilantThe Mirati Therapeutics (NASDAQ:MRTX) Share Price Gained 1921% And Shareholders Are Jubilant
finance.yahoo.com - November 3 at 12:16 PM
Better Buy: Mirati Therapeutics vs. AmgenBetter Buy: Mirati Therapeutics vs. Amgen
www.fool.com - November 2 at 9:13 AM
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer TherapeuticsMirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
finance.yahoo.com - October 28 at 6:13 PM
Mirati drug shrinks tumors in some cancer patients in early-stage trialMirati drug shrinks tumors in some cancer patients in early-stage trial
www.cnbc.com - October 28 at 4:35 PM
Mirati Therapeutics (MRTX) Shares Cross Above 200 DMAMirati Therapeutics (MRTX) Shares Cross Above 200 DMA
www.nasdaq.com - October 25 at 7:00 PM
Mirati Therapeutics, Inc. (MRTX): Are Hedge Funds Right About This Stock?Mirati Therapeutics, Inc. (MRTX): Are Hedge Funds Right About This Stock?
finance.yahoo.com - October 25 at 1:59 PM
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual MeetingMirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
finance.yahoo.com - October 23 at 7:06 PM
Is Mirati Therapeutics a Good Stock to Buy Now?Is Mirati Therapeutics a Good Stock to Buy Now?
www.fool.com - October 20 at 4:46 PM
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer TherapeuticsMirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
finance.yahoo.com - October 17 at 1:22 PM
After 500% Surge, Mirati’s Day of Reckoning Is ApproachingAfter 500% Surge, Mirati’s Day of Reckoning Is Approaching
finance.yahoo.com - October 7 at 12:52 PM
Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?
finance.yahoo.com - October 1 at 4:37 PM
Heres Why Were Not Too Worried About Mirati Therapeuticss (NASDAQ:MRTX) Cash Burn SituationHere's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn Situation
finance.yahoo.com - September 28 at 3:37 PM
Here's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn SituationHere's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn Situation
finance.yahoo.com - September 28 at 3:37 PM
4 Biotech Stocks With Big Catalysts in September4 Biotech Stocks With Big Catalysts in September
finance.yahoo.com - September 6 at 2:51 PM
Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record HighAmgen’s ‘White Whale’ Cancer Data May Send Shares to Record High
finance.yahoo.com - September 5 at 5:13 PM
A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)
finance.yahoo.com - August 23 at 11:54 PM
Mirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of SharesMirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of Shares
finance.yahoo.com - August 23 at 11:54 PM
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human ResourcesMirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
finance.yahoo.com - August 15 at 7:49 PM
Mirati: Lead Candidate Shows Superiority Over Opdivo In NSCLCMirati: Lead Candidate Shows Superiority Over Opdivo In NSCLC
seekingalpha.com - August 13 at 11:47 PM
Mirati Therapeutics Reports Second Quarter 2019 Financial ResultsMirati Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 5 at 11:40 PM
Encouraging data on Amgens AMG 510 stokes Mirati, up 9%Encouraging data on Amgen's AMG 510 stokes Mirati, up 9%
seekingalpha.com - July 31 at 11:55 PM
Mirati Is The Biotech To Watch As Second Half Catalyst Rapidly ApproachesMirati Is The Biotech To Watch As Second Half Catalyst Rapidly Approaches
seekingalpha.com - July 18 at 7:13 PM
Wainwright sees 310% upside in Outlook Therapeutics in premarket analyst actionWainwright sees 310% upside in Outlook Therapeutics in premarket analyst action
seekingalpha.com - July 18 at 8:39 AM
Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair?Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair?
finance.yahoo.com - July 18 at 8:39 AM
How This Novartis Mashup Could Validate A Biotech Company's Cancer DrugHow This Novartis Mashup Could Validate A Biotech Company's Cancer Drug
finance.yahoo.com - July 10 at 6:51 PM
Mirati Inks Deal with Novartis to Evaluate Tumor CandidateMirati Inks Deal with Novartis to Evaluate Tumor Candidate
finance.yahoo.com - July 10 at 6:51 PM
Mirati teams up with Novartis on doublet cancer therapyMirati teams up with Novartis on doublet cancer therapy
seekingalpha.com - July 9 at 6:42 PM
Mirati Therapeutics Still Has Room To GrowMirati Therapeutics Still Has Room To Grow
seekingalpha.com - July 9 at 6:42 PM
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
finance.yahoo.com - July 9 at 6:42 PM
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of DirectorsMirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
finance.yahoo.com - July 1 at 6:55 PM
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel